Previous Article | Next Article 
Journal of Virology, October 1998, p. 7754-7761, Vol. 72, No. 10
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Recombinant Measles Viruses with Mutations in the
C, V, or F Gene Have Altered Growth Phenotypes In Vivo
Alexandra
Valsamakis,1
Henriette
Schneider,2
Paul G.
Auwaerter,1
Hideto
Kaneshima,3
Martin A.
Billeter,2 and
Diane
E.
Griffin1,*
Molecular Microbiology and Immunology, Johns
Hopkins School of Hygiene and Public Health, Baltimore,
Maryland1;
University of Zurich, Zurich,
Switzerland2; and
SyStemix, Palo Alto,
California3
Received 29 April 1998/Accepted 11 June 1998
 |
ABSTRACT |
An understanding of the determinants of measles virus (MV)
virulence has been hampered by the lack of an experimental model of
infection. We have previously demonstrated that virulence phenotypes in
human infections are faithfully reproduced by infection of human
thymus/liver (thy/liv) implants engrafted into SCID mice, where the
virus grows primarily in stromal cells but induces thymocyte apoptosis
(P. G. Auwaerter et al., J. Virol. 70:3734-3740, 1996). To
begin to elucidate the roles of the C protein, V protein, and the 5'
untranslated region of the F gene (F 5'UTR) in MV infection in vivo,
the replication of strains bearing mutations of these genes was
compared to that of the parent sequence-tagged Edmonston strain
(EdTag). Growth curves show that mutants fall into two phenotypic
classes. One class of mutants demonstrated kinetics of growth similar
to that of EdTag, with decreased peak titers. The second class of
mutants manifested peak titers similar to that of EdTag but had
different replication kinetics. Abrogation of V expression led to
delayed and markedly prolonged replication. Additionally, thymocyte
survival was prolonged and implant architecture was preserved
throughout the course of infection. In contrast, massive bystander
thymocyte death occurred after infection with EdTag and all other
mutants. A mutant which overexpressed V in Vero cells (V+) had the
opposite phenotype of the A mutant not expressing V (V
). V+ grew more
rapidly than EdTag with 100-fold-greater levels of virus production 3 days after infection. These results suggest that C, V, and the F 5'UTR
are accessory factors required for efficient virus replication in vivo.
In addition, thymocyte survival after V
infection suggests this
protein may play multiple roles in pathogenesis of MV infection of
thymus. Since these recombinant mutant viruses grew identically to the
parent virus in Vero cells, the data show that thy/liv implants are an
excellent model for investigating the determinants of MV virulence.
 |
INTRODUCTION |
Measles virus (MV), a
negative-strand RNA virus, was originally propagated in tissue culture
by Enders and Peebles in 1954 (15). However, investigation
of the molecular determinants of MV replication has been difficult, and
the functions of a number of genes and control regions remain unknown.
The rescue of infectious virus from a transfected cDNA clone has
enabled the construction of the first recombinant mutant MVs
(39) and has greatly facilitated such studies. The
recombinant viruses examined to date grow identically to the parent
virus in Vero cells (38, 39, 43), suggesting that the
mutated genes and control regions are dispensable for MV replication in
this cell line. The effects of these mutations on MV replication in
vivo are not understood, in part because there is no small-animal model
for measles.
We have previously used a human thymus xenograft, the SCID-hu thy/liv
model, to characterize the replication and pathologic changes induced
by vaccine and wild-type strains of MV known to differ in virulence
(2). Thymus implants are created by coinoculation of human
liver and thymus tissue under the renal capsule of a SCID mouse. Thymus
cells give rise to the thymic microenvironment, and liver cells provide
a source of hematopoietic precursors that populate the developing
thymus (33). Three to four months postengraftment, a
structurally and functionally normal thymus is formed. This model has
been used to study the virulence of a number of other human viruses
that lack small-animal models, including human immunodeficiency virus
(HIV) (4, 22), cytomegalovirus (5, 30), and
varicella-zoster virus (31, 32).
The SCID-hu thy/liv implant is a relevant model for examining the
replication of MV strains in vivo since MV infects the thymus in
natural disease. MV antigens and viral cytopathic effect have been
found in thymus at autopsy following acute infection of humans (50) and at necropsy after experimental infection of
primates (42). In vitro, primary cultures of human thymic
stromal cells support MV growth (34). In addition, in vivo
virulence phenotypes of MV are faithfully reproduced in thy/liv
implants (2). Infection with the minimally passaged patient
isolate Chicago-89 (Chi-1) strain results in high levels of virus
replication in stromal cells and macrophages after 3 days of infection
and massive thymocyte death. In contrast, growth of an attenuated
Moraten vaccine strain is slow and causes little thymocyte death.
We have utilized the SCID-hu thy/liv system to investigate the role of
the 5' untranslated region of the F gene (F 5'UTR), the C protein, and
the V protein in MV growth in vivo. Among the paramyxoviruses, only the
F mRNAs of the morbilliviruses contain a long 460- to 580-nucleotide
GC-rich region between the transcription start site and the methionine
initiation codon. This region has been predicted to have extensive
secondary structure (41). Experiments to define its function
suggest that the F 5'UTR acts as a focusing factor, directing
translation initiation from the second of four clustered AUGs
(8). In addition, this region affects the efficiency of F
translation. In DNA vaccination studies, the MV F 5'UTR is required for
an effective anti-F antibody response in mice and therefore presumably
for the expression of F (47). It is also required for
rinderpest and canine distemper virus F-protein expression in
immortalized cells using vaccinia virus-encoded T7 polymerase to
express F mRNA (16). However, in other vaccinia
virus-encoded T7 polymerase expression studies, partial deletion of the
MV F 5'UTR results in increased F expression (10), and in
rabbit reticulocyte lysates, the 5'UTR inhibits rinderpest and canine distemper virus F translation (16), suggesting that this
region can also inhibit F translation.
The C protein is a small (~20-kDa), positively charged protein
encoded within the P open reading frame (ORF) of the morbilliviruses and paramyxoviruses but not the rubulaviruses. MV expresses a single C
protein from an alternative methionine downstream from the initiator
for the P ORF (3). In Sendai virus (SeV) infection, a nested
set of four C proteins, (C', C, Y1, and Y2) with different translation
initiation sites and common COOH termini are expressed (13, 18,
36). A number of studies have failed to identify C in purified
virions, leading to its designation as a nonstructural protein.
However, recent studies of SeV have found small amounts of C associated
with the nucleocapsid in purified virions (51). In infected
cells, C is found in the nucleus and the cytoplasm, where it
colocalizes with nucleocapsids (3). The function of C is not
clear. Studies with SeV suggest that C inhibits mRNA and antigenomic
RNA synthesis (6, 45), perhaps through direct binding to L,
the catalytic subunit of the viral polymerase (19). Whether
C regulates MV polymerase in a similar manner is unknown.
The V protein is an ~40-kDa protein expressed from the P ORF of all
paramyxoviruses except respiratory syncytial virus and parainfluenza
virus types 1 and 3. In the paramyxovirus and morbillivirus families, V
is a nonstructural protein synthesized as a result of polymerase
slippage at a distinct site within the P ORF which leads to the
pseudotemplated insertion of a single G residue (9, 12, 48).
Thus, the amino terminus of V (231 amino acids in MV) is identical to
that of P, acidic, and highly phosphorylated. The carboxy terminus is
unique to the V protein (68 amino acids in MV), is highly conserved
among the paramyxoviruses, and contains a cysteine-rich zinc finger
domain which binds zinc (27). V is distributed diffusely in
the nucleus and cytoplasm of infected cells and does not colocalize
with nucleocapsids (12, 49). Analysis of SeV V
function in transfected cells suggests that it inhibits genome
replication by binding soluble nucleoprotein (20). In
coimmunoprecipitation studies, MV V appears to bind a number of
cellular proteins (28), but the relevance and role of these
interactions are not yet clear.
The rubulaviruses encode V proteins which are structurally and
functionally different from paramyxovirus and morbillivirus V proteins.
Rubulavirus V proteins are structural proteins which associate with the
nucleocapsid (35, 44). They are encoded directly in the
viral genome (44, 46) and have shorter, basic amino termini.
In simian virus 5, this region binds RNA and nucleoprotein (26,
37, 40). Like those of SeV and MV, the carboxy terminus of
rubulavirus V is cysteine rich and binds zinc (35).
MV mutants which have a deletion of the F 5'UTR or mutations abrogating
expression of C and V (C
and V
mutants) grow like the parent virus
in Vero cells (38, 39, 43), and the growth of SeV V
is
unaltered in a variety of cell lines (14). To determine whether these genes play a role in MV replication in vivo, we have
studied the replication of these mutants in the SCID-hu thy/liv model.
In addition, the growth of a virus with a mutation which results in a
two- to fivefold increase in levels of V has been characterized. The F
5'UTR and C protein may be accessory elements required for efficient
virus growth since peak titers of mutant viruses were lower than those
for the parent. Production of virus was delayed and prolonged in the
absence of V, while excess V resulted in more rapid viral replication.
Data showing that thymocyte and implant survival are prolonged despite
the production of large amounts of virus late after infection with the
V
mutant suggest V may also play an additional role in pathogenesis
of MV infection of thymus.
 |
MATERIALS AND METHODS |
Viruses and cells.
EdTag, del5F, C
, V
, and V+ strains
were constructed and rescued as described previously (38, 39,
43). Vero cells (American Type Culture Collection) were used for
growth of virus stocks and plaque assays. Viruses were diluted in
Dulbecco modified Eagle medium (DMEM; GIBCO, Grand Island, N.Y.)
containing 2% fetal calf serum (FCS; GIBCO) prior to inoculation.
Infection of thy/liv implants.
Implants were engrafted under
the renal capsule of male homozygous CB-17 scid/scid mice as
described previously (33). For infection, SCID-hu mice were
anesthetized with metofane. The left kidney was dissected and
externalized. Visible implants were inoculated with 1,000 PFU of virus
in 25 µl, using a tuberculin syringe. On the day of harvest, mice
were sacrificed and the left kidney with associated implant was removed
en bloc. Implants were then divided into thirds for plaque assay, cell
counts, and histology. For plaque assay and cell counts, implants were
dissected away from the underlying kidney. For histologic analysis, the
kidney was not removed.
Virus growth in thy/liv implants.
MV growth was assessed by
plaque assay. One third of each implant was homogenized in 1 ml of DMEM
containing 10% FCS, and serial 10-fold dilutions of this stock were
titered. Vero cell monolayers were incubated with the inoculum for 60 min at 37°C, overlaid with 0.6% agar-MEM-1% FCS, and incubated
for 5 days at 37°C. Plaques were visualized by staining with 1%
crystal violet after fixation with 9% formaldehyde-phosphate-buffered
saline (PBS). The statistical significance of plaque assay data was
assessed by Student's t test, using StatView software
(Abacus Concepts, Berkeley, Calif.). Samples showing no growth were
assumed to be inoculum failures and were excluded from calculation of
the geometric mean titer unless histologic evidence of viral cytopathic
effect was present. For statistical analysis, these samples were
assigned a value of 1.4 (log10), a value just below the
sensitivity of detection of the plaque assay. A single data point
(EdTag, day 7 postinfection) which differed from the mean by more than
2 standards of deviation was excluded from analysis.
Thymocyte cell number and flow cytometric analysis.
On the
day of harvest, one third of each implant was gently disrupted between
glass microscope slides into PBS-2% FCS. Organ debris was removed by
filtration through 30-µm-pore-size nylon (SpectraMesh, Spectrum,
Houston, Tex.). Viable cells were quantitated by staining an aliquot of
the cell suspension with 0.05% trypan blue. For flow cytometric
analysis, 106 cells were stained with fluorescein
isothiocyanate (FITC)-labeled anti-CD3 antibody (PharMingen, San Diego,
Calif.) for 60 min at 4°C. In the final 15 min of staining, propidium
iodide (PI; Molecular Probes, Eugene, Oreg.) was added to stain dead
thymocytes. Cells were then washed twice with PBS-2% FCS and analyzed
with FACSCaliber instrumentation (Becton Dickinson, Mountain View,
Calif.); 105 ungated fluorescent events were acquired. Data
were analyzed with CellQuest software (Becton Dickinson). The
mononuclear cell population displaying variable size and low complexity
on forward and side scatter plots was gated for analysis of CD3 and PI
staining. Small, low-complexity events representing debris were
excluded from analysis.
Thymus histology and immunofluorescence assay.
For
histologic analysis, one third of each implant was either fixed for 24 to 72 h in 4% paraformaldehyde (PF)-PBS or frozen in Tissue-Tek
OCT (Miles, Elkhart, Ind.) on dry ice. After embedding in paraffin,
PF-fixed implants were cut into 4-µm sections and stained with
hematoxylin and eosin. For detection of MV and cellular antigens,
frozen implants were cut into 5- to 7-µm sections. Sections were
allowed to dry almost to completion to facilitate adherence to slides
and then kept moist in PBS-2% FCS at 4°C to preserve viral and
cellular antigens prior to fixation. Sections were fixed in acetone for
5 min at
20°C and allowed to dry briefly. After fixation, slides
were kept horizontal to prevent loss of thymocytes in subsequent
incubations. Prior to staining, sections were blocked with PBS-2%
FCS. MV antigens were detected by indirect staining with a cocktail of
monoclonal antibodies against N (N25; WHO Antibody Bank), M (CV-7; gift
of Paul Rota), and H (NC32; gift of Bracha Rager-Zisman), each at 1:200
in PBS-2% FCS, followed by biotinylated goat anti-mouse
immunoglobulin G (10 µg/ml; Molecular Probes) and streptavidin Texas
red (Dupont NEN, Boston, Mass.). Cytokeratin (clone C-11; Sigma, St.
Louis, Mo.) and CD15 (clone DU-HL60-3; Sigma) were detected by direct
staining using FITC-conjugated primary antibodies. Indirect staining
preceded direct staining. All blocking and antibody incubation steps
were performed for 60 min at 4°C. Sections were washed three times
with ice-cold PBS after each incubation. Coverslips were mounted by
using PermaFluor aqueous medium (Immunon, Pittsburgh, Pa.).
Immunofluorescence was assessed by epifluorescence microscopy using
Nikon Eclipse instrumentation.
Sequence analysis of recovered viruses.
Virus stocks for
sequence analysis were prepared by passaging homogenates from plaque
assays twice on Vero cells. Total cellular RNA was recovered after the
second passage with RNAStat (TelTest, Friendswood, Tex.) according to
the manufacturer's protocol. MV RNA was amplified by reverse
transcription (RT)-PCR. cDNA synthesis reaction mixtures consisted of
one half of the recovered RNA, 250 µM deoxynucleoside triphosphates
(Boehringer Mannheim, Indianapolis, Ind.), 8 mM dithiothreitol
(GIBCO-BRL), 20 U of RNasin (Promega Biotech, Madison, Wis.), 0.8 µg
of random hexamer oligonucleotides (Boehringer Mannheim), 1× RT buffer
(GIBCO-BRL), and 200 U of SuperScriptII (GIBCO-BRL). Prior to use in RT
reactions, RNA was heated to 70°C for 5 min and cooled at room
temperature for 5 min. RT reaction mixtures were incubated at 37°C
for 60 min. PCR mixtures contained 5 µl of cDNA, 200 µM nucleoside
triphosphates (Boehringer Mannheim), 1.25 U of Taq
polymerase (Boehringer Mannheim), 1× PCR Buffer (Boehringer Mannheim),
and 200 nM each primer. Primers used to amplify the region surrounding
the editing site within the P cistron were
5'-GCTCCTGAGACTCCAATC-3' (forward) and
5'-GGGATCTCGGGGAATTG-3' (reverse). PCR cycling conditions
consisted of 95°C for 1 min, followed by 30 cycles of 95°C for
15 s and 55°C for 30 s. PCR products were finished with
60°C incubation for 6 min. Following PCR, amplified fragment size was
assessed by agarose gel electrophoresis. PCR products from reactions
that amplified a fragment of expected length were further purified on
Qiaquick columns (Qiagen, Santa Clarita, Calif.) according to the
manufacturer's protocol. Eluted products were resuspended in distilled
water and sequenced with a primer complementary to a sequence internal
to the synthesized fragment (5'-CTCCGCCCCCGGACCCCG-3'),
using ABI Prism instrumentation (Perkin-Elmer, Foster City,
Calif.) at the Johns Hopkins DNA Synthesis Core Facility.
 |
RESULTS |
Replication of recombinant MV strains in thy/liv implants.
The
growth of five recombinant MV strains, the parental virus and four
mutant viruses, was assessed in thymic implants (Fig. 1). The recombinant parental virus
(EdTag) is an extensively passaged, molecularly cloned, sequenced
derivative of the Edmonston B strain of MV. Three nucleic acid
substitutions in the noncoding region between N and P genes were
introduced to allow the distinction of recombinant virus from the
standard Edmonston B strain. Four mutant viruses were constructed in
this background to allow assessment of the function of the F 5'UTR and
the C and V proteins (Fig. 1). The mutations consisted of a
504-nucleotide deletion of the 5' noncoding region of the fusion gene
(del5F), two nucleotide substitutions altering the initiator methionine
codon and creating a new stop codon six amino acids into the C ORF
(C
), a single nucleotide substitution which abrogates the recognition
of the editing site in the P ORF required for the synthesis of V mRNA (V
), and insertion of three G residues at the P ORF editing site (V+)
which increases V expression two- to fivefold in Vero cells (43). Three nucleotides were deleted in the H-L intergenic
region of this virus in order to preserve the rule of six.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 1.
Recombinant MVs. Nucleotides representing site-specific
mutations are shown in boldface. (A) The three nucleotide changes in
the noncoding region between N and P in EdTag are indicated. These
changes are also present in all mutant constructs. (B) The
504-nucleotide (nt) deletion of the F 5'UTR of del5F is indicated by
the thin line. (C) The wild-type initiation methionine and tryptophan
codon six amino acids downstream are indicated above the C gene.
Mutations are shown below. The first mutation was predicted to
inactivate the initiator methionine. The second mutation created a stop
codon after the first five amino acids of the C ORF. (D) V-mutant,
created by a single A-to-G substitution shown in boldface within the P
ORF. , shared amino terminus of V and P; , unique carboxy
terminus of V. (E) V+, insertion of three G residues at the editing
site within the P ORF shown in boldface. Boxes and shading as in panel
D.
|
|
Implants were inoculated directly with 10
3 PFU of virus and
were harvested at various times postinfection. The parental virus
EdTag
reached peak titer of approximately 10
5 PFU/third of
implant between 3 and 7 days postinfection (Fig.
2). Titers declined 100-fold by 28 days
postinfection, presumably
due to virus-induced death of the susceptible
cells. Growth of
the mutant viruses in thy/liv implants was distinct
from that
of EdTag. The peak titers for del5F and C

were 10-fold less
than
that of EdTag (Fig.
2A and C; C

,
P = 0.02;
del5F,
P = 0.007),
but the kinetics of replication
differed only slightly. Virus
production 4 days after infection was
10-fold greater in del5F-infected
than in EdTag-infected implants, but
this difference did not reach
statistical significance
(
P = 0.08). EdTag reached a peak at day
7 and declined
thereafter, while C

and del5F continued at peak
levels of replication
through day 14 postinfection and then declined
at a rate similar to
that for EdTag (Fig.
2A).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 2.
Growth of recombinant mutant MVs in SCID-hu thy/liv
implants. Implants were infected with 103 PFU of virus and
harvested at various times postinfection. (A) Growth of C and del5F
compared to that of EdTag; (B) growth of V and V+ compared to that of
EdTag. Each point is the geometric mean of 2 to 10 mice. Error bars
indicate the standard errors of the means. (C) Scatter plot of the
amount of virus in individual implants 7 days after infection. The
dotted line represents the lower limit of detection of the plaque
assay. Data from four different experiments are shown.
|
|
Occasionally, virus was not detected by plaque assay after inoculation
of implants. Such implants were excluded from calculation
of the
geometric means (Fig.
2A) and thymocyte viability (Fig.
3) unless there was evidence of viral
cytopathic effect. A lack
of growth was observed most often in implants
infected with the
C

mutant (4 of 8 implants [Fig.
2C]) but was also
seen in implants
inoculated with EdTag (2 of 10 implants) and del5F (1 of 11 implants)
7 days after infection (Fig.
2C). It is unclear whether
the lack
of growth in a greater number of implants infected with C

was
due to technical reasons since the data were obtained from four
separate inoculations.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 3.
Effect of recombinant mutant MV infection on numbers of
viable thymocytes in SCID-hu thy/liv implants. Thymocytes were released
from implants, and viability was assessed by trypan blue exclusion.
Points represent the geometric means of data from implants which were
used in the calculation of geometric mean titers in Fig. 2. Error bars
indicate the standard errors of the means. (A) Effects of infection
with del5F, C , and EdTag on thymocyte survival compared to EdTag; (B)
Effect of infection with V , V+, and EdTag on thymocyte survival.
|
|
V

and V+ viruses grew with kinetics substantially different from
those for EdTag. V

replication was delayed and prolonged.
Peak titer
was achieved by day 14 for V

, compared to day 7 postinfection
for
EdTag, and large amounts of virus continued to be produced
28 days
after infection (Fig.
2B). At 47 days after infection,
V

mutant-infected implants were still producing high levels of
virus
(mean titer, 4.4 log
10 PFU/third of implant). In contrast,
V+ grew rapidly, producing 100-fold more virus than EdTag after
4 days
of infection (
P = 0.02 [Fig.
2B]). Viral replication
continued
at high levels until day 14 postinfection and decreased in
parallel
with EdTag through 28 days postinfection. Peak titers for V

,
V+, and EdTag were not significantly different. All thy/liv-passaged
mutant strains demonstrated plaque morphologies comparable to
that of
EdTag on Vero cells.
Effect of recombinant MV replication on implant thymocytes.
Previous study of MV replication in thy/liv implants demonstrated that
MV infects thymic stromal epithelial cells and cells of the
monocyte/macrophage lineage but not thymocytes. However, thymocyte
apoptosis and a decline in thymocyte number is induced by infection
with virulent strains. To assess the effect of recombinant mutant MV
infection on thymocyte viability, thymus cells were collected at
various times after infection. Viability was assessed by light
microscopy using trypan blue exclusion and by flow cytometry using PI
coupled with anti-CD3 for identification of thymocytes. C
and del5F
caused a 10-fold decrease in the numbers of viable cells 28 days after
infection, which was similar to that caused by EdTag (Fig. 3A). A
decrease in mononuclear cells was also seen by flow cytometry. Forward
and side scatter plots showed predominantly debris with a reduction of
events in the mononuclear cell region (Fig. 4A). Very few
CD3+ PI
cells remained 28 days postinfection
(Fig. 4B).
Virus mutants which had opposing effects on growth kinetics also had
opposing effects on thymocyte viability within infected
implants. After
28 days, viable thymocyte numbers declined 10-fold
in implants infected
with V+, similar to the effect of EdTag (Fig.
3B). This decrease was
confirmed by flow cytometry, which demonstrated
a reduction in the
number of CD3
+ PI

cells in the mononuclear
cell region (Fig.
4). In contrast,
although
implants infected with the V

mutant continued to produce
high
levels of virus, numbers of viable thymocytes declined less than
fivefold after 28 days of infection. By flow cytometry, a large
number
of events were still detected in the mononuclear cell gate
(Fig.
4A),
and the percentage of CD3
+ PI

cells in the
total population changed minimally (Fig.
4B).

View larger version (17K):
[in this window]
[in a new window]

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 4.
CD3 and PI staining of thymocytes from infected
implants. A total of 106 cells from disrupted implants were
stained with CD3 and PI and analyzed by flow cytometry. (A)
Representative forward and side scatter plots of thymocytes from
implants 28 days after infection. Flow cytometry data for all mutants
were analyzed by using gates depicted in the EdTag plot.
CD3+ PI live mononuclear cells were found in
the region indicated by R2. Debris and dead cells were found in R5. (B)
Percentage of cells in the total population which were CD3+
PI . Each bar represents data from three different
implants. Error bars indicate the standard errors of the means.
|
|
Effect of MV replication on implant architecture.
The
histologic morphology of MV-infected thy/liv implants was assessed by
hematoxylin-and-eosin staining. In previous studies, implants infected
with the low-passage-number MV isolate Chi-1 manifested marked
thymocyte pyknosis and nuclear condensation by day 4 and complete loss
of thymocytes by day 14 (2). The onset and progression of
histopathologic changes was slower in implants infected with EdTag.
Thymus morphology was relatively normal through 14 days postinfection
(data not shown). However, the effects of viral replication were
evident by 28 days postinfection, when implants infected with EdTag,
del5F, C
, and V+ demonstrated marked cortical and medullary thymocyte
loss and thymic involution (Fig. 5),
providing histologic correlation of the effect of these viruses on
thymocyte number. In marked contrast, the histology of thymuses
infected with the V
mutant strain remained similar to that of
mock-infected implants even after 47 days of infection (Fig. 5F).

View larger version (70K):
[in this window]
[in a new window]
|
FIG. 5.
Histology of implants 28 to 47 days after infection with
recombinant mutant MVs. One third of each implant was fixed in 4%
PF-PBS. Sections were stained with hematoxylin and eosin. Attached
renal tissue lies underneath thymus implants. (A) Mock-infected implant
showing intact cortical and medullary zones, day 28; (B) EdTag, day 28;
(C) del5F, day 28; (D) C , day 28; (E) V+, day 28; (F) V , day 47. Magnifications: A, ×16; B to F, ×20.
|
|
Localization of V
replication thy/liv implants.
To determine
whether V
retained the in vivo cellular tropism of EdTag, the cell
types infected by the V
mutant were identified by dual-label
immunofluorescence. Infected cell types were identified by costaining
with anti-CD15 antibody to identify resident monocytes/macrophages or
with anticytokeratin antibody to identify thymic stromal epithelial cells. MV antigens were found in medullary zones and colocalized with
cells expressing CD15 (Fig. 6D to F) and
cytokeratin (Fig. 6A to C) in V
mutant-infected implants. In
addition, MV antigens were found in Hassall's corpuscles adjacent to
MV-infected stromal cells (Fig. 6A to C). A similar pattern of
colocalization and distribution was demonstrated in implants infected
with EdTag (data not shown) and the Chi-1 isolate of MV (2).
No immunofluorescence was detected on sections of MV-infected implants
stained with secondary antibody and avidin Texas red or on sections of
mock-infected implants stained with the cocktail of monoclonal anti-MV
antibodies, demonstrating that indirect staining for MV antigens was
specific. These results suggest that the altered phenotype of the V
strain cannot be explained by a change in cell tropism.

View larger version (70K):
[in this window]
[in a new window]
|
FIG. 6.
Immunofluorescence staining of thy/liv implant infected
with V . At day 7 postinfection, one third of an implant was frozen in
OCT. Sections were stained for MV antigens by using monoclonal
antibodies against H, N, and M followed by biotinylated anti-mouse
immunoglobulin G and streptavidin Texas red (B and E). Cell types were
labeled with FITC-conjugated anticytokeratin antibody (A) or
FITC-conjugated anti-CD15 antibody (D). (C) Colocalization of
immunofluorescence in panels A and B. (F) Colocalization of
immunofluorescence in panels D and E.
|
|
Sequence of viruses recovered from infected implants.
To
determine whether a reversion of the editing site mutation occurred in
V
mutant-infected implants after 28 days of replication, isolated
virus was sequenced. A virus stock was prepared from homogenates used
in plaque assays by passage on Vero cells. MV-specific sequences were
amplified by RT-PCR. The original A-to-G mutation was still present
(data not shown). Similar experiments with RNAs from amplified stocks
of EdTag, C
, del5F, and V+ viruses demonstrated that all original
mutations were still present after 14 days of growth in thy/liv
implants (data not shown).
 |
DISCUSSION |
To begin to understand the molecular determinants of MV growth in
vivo, we have studied the replication of four recombinant MV strains,
with mutations in genes or gene regions of unknown function, in a
unique human thymus model which faithfully duplicates in vivo virulence
phenotypes of MV (2). The data show that these mutant
strains have altered growth characteristics in vivo. Deletion of the F
5'UTR and abrogation of C expression resulted in decreased peak virus
production and small changes in the kinetics of growth. The effects of
these viruses on implant architecture and thymocyte death were similar
to those of the parent EdTag. In contrast, mutations which affected V
expression altered the kinetics of virus growth but had no effect on
peak virus production. The kinetics of virus growth correlated with the
level of V expression. V
, which fails to express V due to an A-to-G
substitution in the fourth position in the editing site, grew slowly,
and growth was prolonged. Large amounts of virus continued to be
produced as late as 47 days postinfection. V+, a mutant which produces elevated levels of V, had the opposite effect on virus growth. High
levels of virus were produced early in infection, suggesting that V
overexpression conferred an initial growth advantage, but growth
declined by 28 days after infection. These two mutant strains also had
opposite effects on thymocyte viability and implant architecture. Infection with V+, like parent virus infection, induced a decline in
thymocytes and disruption of implant architecture. In contrast, thymocytes were only minimally affected by V
infection and implant architecture remained well preserved.
EdTag, the parent virus in these studies, is a derivative of Edmonston
B which has been passaged extensively in tissue culture cells. Despite
its passage history, this virus grew well in thy/liv implants. However,
it did show some signs of attenuation. Peak virus production was
reduced approximately 10-fold compared to Chi-1, a patient isolate
which has been passaged minimally. EdTag also grew more slowly than
Chi-1, producing peak titers at 7 days rather than 3 days after
infection, and viral cytopathic effect occurred later. Finally,
thymocyte apoptosis, which correlates with virus virulence
(2), was delayed after infection with EdTag. Implants were
largely devoid of thymocytes by 14 days postinfection with Chi-1,
compared to 28 days after infection with EdTag.
The growth of del5F, C
, and V
in SCID-hu thy/liv implants
demonstrates that the F 5'UTR, the C protein, and the V protein are not
absolutely required for MV replication in this system. However, they
may have accessory functions required for efficient MV replication
given the phenotypes of decreased peak virus production and altered
growth kinetics seen in viruses with mutations in these genes.
Additionally, construction of these mutations in the parental
background of a more virulent virus like Chi-1 might result in more
dramatic effects on virus growth.
The effect of the F 5'UTR on F expression during MV infection of the
thy/liv implant is unknown. The phenotype of the del5F mutant in
thy/liv implants is consistent with a functional alteration leading to
a change in the level, but not the abrogation, of F expression. To
determine the effect of this deletion in thy/liv implants, it will be
important to characterize the level of F mRNA and protein expression. A
decrease in F expression would suggest that the F 5'UTR acts as a
positive regulator of translation. However, the phenotype of an early
growth advantage combined with decreased peak titer observed for the
del5F mutant is also consistent with a negative regulatory activity of
the F 5'UTR. High levels of F synthesis might lead to increased virus
production early in infection and might also cause premature fusion and
death of infected cells prior to peak virus production. Additionally,
it is possible that the function of the F 5'UTR is partially preserved since approximately 70 nt of this region are present in the del5F mutant. Construction and testing of a mutant bearing a deletion of the
remaining sequence will be required to fully assess the function of the
5'UTR.
The phenotypes of V
and V+ suggest that V expression regulates the
rate of MV growth in thy/liv implants. V expression also affects the
growth of SeV in vivo. However, unlike the delayed and prolonged growth
of MV V
, virus production in the lungs of immunocompetent mice
infected with SeV V
mutants declines rapidly after an initial rise
(23, 24). Viral antigen expression is also reduced and
restricted within the respiratory epithelium (23). The in
vivo observations for these two viruses are apparently conflicting but
may be explained by differences in immune responses. In the lungs of
immunocompetent mice, inefficient virus spread may facilitate early
activation of a local immune response and lead to accelerated SeV
clearance. The SCID mice with thy/liv implants cannot mount antiviral
B- and T-cell responses. Thus, inefficient spread may lead to delayed
and prolonged growth. How the V protein might control virus spread is
unclear. The SeV V protein binds soluble nucleoprotein and inhibits
genomic RNA synthesis. Inefficient spread might result from aberrant
regulation of genomic RNA synthesis. Alternatively, the V protein may
have other novel functions in vivo or different roles in the
pathogenesis of MV and SeV infection.
Prolonged viral replication combined with thymocyte and implant
survival after infection with the MV V
strain suggests that V may
play a role in MV pathogenesis in addition to growth regulation. Dual-immunofluorescence studies suggest that these observations cannot
be accounted for by a change in tropism leading to loss of the ability
of MV V
to infect stromal epithelial cells. An alternative hypothesis
to explain sustained virus production and thymocyte survival is that V
plays a role in a process leading to the death of infected cells. In
the absence of V, infected stromal epithelial cells and monocytes would
survive, virus replication would continue, and thymocytes would remain
viable because trophic signals required for survival, such as
interleukin-7, would be maintained. Alternatively, V might induce
signals which cause thymocyte apoptosis such as Fas ligand, tumor
necrosis factor, or local production of glucocorticoids. However, this
hypothesis does not account for continued virus production. It is also
possible that altered virus growth and thymocyte survival are due to
increased P expression rather than decreased V expression since
mutation of the editing site would result in the exclusive synthesis of phosphoprotein from the P ORF. In infection with the Edmonston strain
of MV, 50% of the mRNA expressed from the P ORF is V mRNA (9).
Since the function of the C protein during MV replication is not well
characterized, the mechanism leading to diminished peak virus
production in implants infected with C
is unclear. In SeV infection,
C may regulate the switch to genomic RNA synthesis by preferentially
inhibiting mRNA and antigenome synthesis from the le+ promoter (6,
45) and may facilitate virus growth by preventing replication
from suboptimal promoters, such as mRNAs that are mistakenly packaged
into nucleocapsids (45). Interestingly, in the lungs of
immunocompetent mice, SeV C
growth declines rapidly, suggesting that
a defect in replication leads to rapid clearance similar to SeV V
(17).
Whether MV C functions like SeV C during infection of thy/liv implants
is unknown. The low peak titer of C
could result from the inefficient
switch to genome synthesis or from decreased polymerase selectivity.
Alternatively, although SeV and MV are related viruses, their
replication mechanisms may not be exactly the same and their C proteins
may have shared but not identical functions. For example, C may enforce
the rule of six, which is observed by both viruses (7, 39,
45). Other C functions may be quite different, as suggested by
the effect of the C protein on the recovery of infectious virus from
transfected plasmids. MV can be rescued from transfected plasmids
expressing C (39), while SeV can be recovered only if C
expression is inhibited (6, 17).
The significance of the inability to detect virus growth in a greater
number of implants infected with C
is unclear. It might be explained
by technical difficulties or implant conditions at the time of
inoculation. However, a variable ability to support MV replication has
also been observed in human peripheral blood lymphocytes infected with
C
(33a). Since MV C associates with cellular proteins
(28), it may regulate virus growth through an interaction
with cellular factors whose expression varies from host to host.
Finally, disparities in the determinants for growth in vitro and in
vivo have been reported for a growing number of viruses. For example,
glycoprotein C is dispensable for growth of herpes simplex virus and
varicella-zoster virus in tissue culture (11, 29), but
viruses lacking expression of glycoprotein C have reduced infectivity
in human skin implants engrafted in SCID mice (32). The
accessory protein Nef is dispensable for HIV and simian
immunodeficiency virus replication in vitro (1, 21, 25), but
mutants bearing nef deletions are severely attenuated in
SCID-hu thy/liv implants (1, 21) and rhesus macaques
(25). Similar results have been demonstrated for the HIV
genes vpu and vif (1). These findings
support one of the fundamental hypotheses of viral pathogenesis, that
the determinants of virus growth in organs comprised of numerous interacting cell types at various stages of differentiation and with
variable capacity to divide are much more complex than those required
for replication of virus in a clonal population of dividing cells
growing in defined tissue culture medium.
 |
ACKNOWLEDGMENTS |
We thank Paul Rota, Bracha Rager-Zisman, and the WHO Antibody
Bank for generous gifts of monoclonal antibodies. We also thank Michael
Teng, Mari Manchester, and Andy Golden for helpful discussion and
suggestions.
This work was supported by research grants from the World Health
Organization (D.E.G.), by grants R01AI23047 (D.E.G.), R01AI35136 (M.A.B.), T32AI07417 (A.V.), and T32AI07541 (A.V.) from the National Institutes of Health, and by grant 31-43475.95 from the Schweizerische Nationalfonds (M.A.B.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Dept. of
Molecular Microbiology and Immunology, School of Hygiene and Public
Health, Johns Hopkins University, 615 N. Wolfe St., Baltimore, MD
21205-2179. Phone: (410) 955-3459. Fax: (410) 955-0105. E-mail:
dgriffin{at}welchlink.welch.jhu.edu.
 |
REFERENCES |
| 1.
|
Aldrovandi, G. M., and J. A. Zack.
1996.
Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mice.
J. Virol.
70:1505-1511[Abstract].
|
| 2.
|
Auwaerter, P. G.,
H. Kaneshima,
J. M. McCune,
G. Wiegand, and D. E. Griffin.
1996.
Measles virus infection of thymic epithelium in the SCID-hu mouse leads to thymocyte apoptosis.
J. Virol.
70:3734-3740[Abstract].
|
| 3.
|
Bellini, W. J.,
G. Englund,
S. Rozenblatt,
H. Arnheiter, and C. D. Richardson.
1985.
Measles virus P gene codes for two proteins.
J. Virol.
53:908-919[Abstract/Free Full Text].
|
| 4.
|
Bonyhadi, M. L.,
L. Rabin,
S. Salimi,
D. A. Brown,
J. Kosek,
J. M. McCune, and H. Kaneshima.
1993.
HIV induces thymus depletion in vivo.
Nature
363:728-732[Medline].
|
| 5.
|
Brown, J. M.,
H. Kaneshima, and E. Mocarski.
1995.
Dramatic intrastrain differences in the replication of human CMV in SCID-hu mice.
J. Infect. Dis.
171:1599-1603[Medline].
|
| 6.
|
Cadd, T.,
D. Garcin,
C. Tapparel,
M. Itoh,
M. Homma,
L. Roux,
J. Curran, and D. Kolakofsky.
1996.
The Sendai paramyxovirus accessory C proteins inhibit viral genome amplification in promoter-specific fashion.
J. Virol.
70:5067-5074[Abstract/Free Full Text].
|
| 7.
|
Calain, P., and L. Roux.
1993.
The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA.
J. Virol.
67:4822-4830[Abstract/Free Full Text].
|
| 8.
|
Cathomen, T.,
D. J. Buchholz,
P. Spielhofer, and R. Cattaneo.
1995.
Preferential initiation at the second AUG of the measles virus F mRNA: a role for the long untranslated region.
Virology
214:628-632[Medline].
|
| 9.
|
Cattaneo, R.,
K. Kaelin,
K. Baczko, and M. A. Billeter.
1989.
Measles virus editing provides an additional cysteine-rich protein.
Cell
56:759-764[Medline].
|
| 10.
|
Cattaneo, R., and J. K. Rose.
1993.
Cell fusion by the envelope glycoproteins of persistent measles viruses which caused lethal human brain diseases.
J. Virol.
67:1493-1502[Abstract/Free Full Text].
|
| 11.
|
Cohen, J. I., and K. E. Seidel.
1994.
Absence of varicella-zoster virus (VZV) glycoprotein V does not alter growth of VZV in vitro or sensitivity to heparin.
J. Gen. Virol.
75:3087-3093[Abstract/Free Full Text].
|
| 12.
|
Curran, J.,
M. DeMelo,
S. Moyer, and D. Kolakofsky.
1991.
Characterization of the Sendai virus V protein with an anti-peptide antiserum.
Virology
184:108-116[Medline].
|
| 13.
|
Curran, J. A., and D. Kolakofsky.
1988.
Ribosomal initiation from an ACG codon in the Sendai virus P/C mRNA.
EMBO J.
7:245-251[Medline].
|
| 14.
|
Delenda, C.,
S. Hausmann,
D. Garcin, and D. Kolakofsky.
1997.
Normal cellular replication of Sendai virus without the trans-frame, nonstructural V protein.
Virology
228:55-62[Medline].
|
| 15.
|
Enders, J. F., and T. C. Peebles.
1954.
Propagation in tissue cultures of cytopathic agents from patients with measles.
Proc. Soc. Exp. Biol. Med.
86:277-286.
|
| 16.
|
Evans, S. A.,
G. J. Belsham, and T. Barrett.
1990.
The role of the 5' nontranslated regions of the fusion protein mRNAs of canine distemper virus and rinderpest virus.
Virology
177:317-323[Medline].
|
| 17.
|
Garcin, D.,
M. Itoh, and D. Kolakofsky.
1997.
A point mutation in the Sendai virus accessory C protein attenuates virulence for mice, but not virus growth in cell culture.
Virology
238:424-431[Medline].
|
| 18.
|
Gupta, K. C., and S. Patwardhan.
1988.
ACG, the initiator codon for a Sendai virus protein.
J. Biol. Chem.
263:8553-8556[Abstract/Free Full Text].
|
| 19.
|
Horikami, S. M.,
R. E. Hector,
S. Smallwood, and S. A. Moyer.
1997.
The Sendai virus C protein binds the L polymerase protein to inhibit viral RNA synthesis.
Virology
235:261-270[Medline].
|
| 20.
|
Horikami, S. M.,
S. Smallwood, and S. A. Moyer.
1996.
The Sendai virus V protein interacts with the NP protein to regulate viral genome RNA replication.
Virology
222:383-390[Medline].
|
| 21.
|
Jamieson, B. D.,
G. M. Aldrovandi,
V. Planelles,
J. B. M. Jowett,
L. Guo,
L. Bloch, and J. A. Zack.
1994.
Requirement of human immunodeficiency virus type 1 Nef for in vivo replication and pathogenicity.
J. Virol.
68:3478-3485[Abstract/Free Full Text].
|
| 22.
|
Jamieson, B. D.,
G. M. Aldrovandi, and J. A. Zack.
1996.
The SCID-hu mouse: an in vivo model for HIV-1 pathogenesis and stem cell gene therapy for AIDS.
Semin. Immunol.
8:215-221[Medline].
|
| 23.
|
Kato, A.,
K. Kiyotani,
Y. Sakai,
T. Yoshida, and Y. Nagai.
1997.
The paramyxovirus, Sendai virus, V protein encodes a luxury function required for viral pathogenesis.
EMBO J.
16:578-587[Medline].
|
| 24.
|
Kato, A.,
K. Kiyotani,
Y. Sakai,
T. Yoshida,
T. Shioda, and Y. Nagai.
1997.
Importance of the cysteine-rich carboxy-terminal half of V protein for Sendai virus pathogenesis.
J. Virol.
71:7266-7272[Abstract].
|
| 25.
|
Kestler, H. W.,
D. J. Ringler,
M. Kazuyasu,
D. L. Panicali,
P. K. Sehgal,
M. D. Daniel, and R. C. Desrosiers.
1991.
Importance of the nef gene for maintenance of high virus loads and for development of AIDS.
Cell
65:651-662[Medline].
|
| 26.
|
Lin, G. Y.,
R. G. Paterson, and R. A. Lamb.
1997.
The RNA binding region of the paramyxovirus SV5 V and P proteins.
Virology
238:460-469[Medline].
|
| 27.
|
Liston, P., and D. J. Briedis.
1994.
Measles virus V protein binds zinc.
Virology
198:399-404[Medline].
|
| 28.
|
Liston, P.,
C. DiFlumeri, and D. J. Briedis.
1995.
Protein interactions entered into by the measles virus P, V, and C proteins.
Virus Res.
38:241-259[Medline].
|
| 29.
|
Manservigi, R.,
P. Spear, and A. Buchan.
1977.
Cell fusion induced by herpes simplex virus is promoted and supported by different glycoproteins.
Proc. Natl. Acad. Sci. USA
74:3913-3917[Abstract/Free Full Text].
|
| 30.
|
Mocarski, E. S.,
M. Bonyhadi,
J. M. McCune, and H. Kaneshima.
1993.
Human CMV in a SCID-hu mouse: thymic epithelial cells are prominent targets of viral replication.
Proc. Natl. Acad. Sci. USA
90:104-108[Abstract/Free Full Text].
|
| 31.
|
Moffat, J. F.,
M. D. Stein,
H. Kaneshima, and A. M. Arvin.
1995.
Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice.
J. Virol.
69:5236-5242[Abstract].
|
| 32.
|
Moffat, J. F.,
L. Zerboni,
P. R. Kinchington,
C. Grose,
H. Kaneshima, and A. M. Arvin.
1998.
Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse.
J. Virol.
72:965-974[Abstract/Free Full Text].
|
| 33.
|
Namikawa, R.,
K. N. Weilbaecher,
H. Kaneshima,
E. J. Lee, and J. M. McCune.
1989.
Long-term human hematopoiesis in the SCID-hu mouse.
J. Exp. Med.
172:1055-1063[Abstract/Free Full Text].
|
| 33a.
| Naniche, D. Personal communication.
|
| 34.
|
Numazaki, K.,
H. Goldman,
I. Wong, and M. A. Wainberg.
1989.
Replication of measles virus in cultured human thymic epithelial cells.
J. Med. Virol.
27:52-58[Medline].
|
| 35.
|
Paterson, R. G.,
G. P. Leser,
M. A. Shaughnessy, and R. A. Lamb.
1995.
The paramyxovirus SV5 V protein binds two atoms of zinc and is a structural component of virions.
Virology
208:121-131[Medline].
|
| 36.
|
Patwardhan, S., and K. C. Gupta.
1988.
Translation initiation potential of the 5' proximal AUGs of the polycistronic P/C mRNA of Sendai virus: a multipurpose vector of site-specific mutagenesis.
J. Biol. Chem.
263:4907-4913[Abstract/Free Full Text].
|
| 37.
|
Precious, B.,
D. F. Young,
A. Bermingham,
R. Fearns,
M. Ryan, and R. E. Randall.
1995.
Inducible expression of the P, V, and NP genes of the paramyxovirus simian virus 5 in cell lines and an examination of NP-P and NP-V interactions.
J. Virol.
69:8001-8010[Abstract].
|
| 38.
|
Radecke, F., and M. A. Billeter.
1996.
The nonstructural C protein is not essential for multiplication of Edmonston B strain measles virus in cultured cells.
Virology
217:418-421[Medline].
|
| 39.
|
Radecke, F.,
P. Spielhofer,
H. Schneider,
K. Kaelin,
M. Huber,
C. Dotsch,
G. Christiansen, and M. A. Billeter.
1995.
Rescue of measles virus from cloned DNA.
EMBO J.
14:5773-5784[Medline].
|
| 40.
|
Randall, R. E., and A. Bermingham.
1996.
NP:P and NP:V interactions of the paramyxovirus simian virus 5 examined using a novel protein:protein capture assay.
Virology
224:121-129[Medline].
|
| 41.
|
Richardson, C.,
D. Hull,
P. Greer,
K. Hasel,
A. Berkovich,
G. Englund,
W. Bellini,
B. Rima, and R. Lazzarini.
1986.
The nucleotide sequence of the mRNA encoding the fusion protein of measles virus (Edmonston strain): a comparison of fusion proteins from several different paramyxoviruses.
Virology
155:508-523[Medline].
|
| 42.
|
Sakaguchi, M.,
Y. Yoshikawa,
K. Yamanouchi,
T. Sata,
K. Nagashima, and K. Takeda.
1986.
Growth of measles virus in epithelial and lymphoid tissues of cynomolgus monkeys.
Microbiol. Immunol.
30:1067-1073[Medline].
|
| 43.
|
Schneider, H.,
K. Kaelin, and M. A. Billeter.
1997.
Recombinant measles virus defective for RNA editing and V protein synthesis are viable in cultured cells.
Virology
227:314-322[Medline].
|
| 44.
|
Takeuchi, K.,
K. Tanabayashi,
M. Hishiyama,
Y. Yamada,
A. Yamada, and A. Sugiura.
1990.
Detection and characterization of mumps virus V protein.
Virology
178:247-253[Medline].
|
| 45.
|
Tapparel, C.,
S. Hausmann,
T. Pelet,
J. Curran,
D. Kolakofsky, and L. Roux.
1997.
Inhibition of Sendai virus genome replication due to promoter-increased selectivity: a possible role for the accessory C protein.
J. Virol.
71:9588-9599[Abstract].
|
| 46.
|
Thomas, S. M.,
R. A. Lamb, and R. G. Paterson.
1988.
Two mRNAs that differ by two nontemplated nucleotides encode the amino coterminal proteins P and V of the paramyxovirus SV5.
Cell
54:891-902[Medline].
|
| 47.
| Valsamakis, A., F. Mustafa, D. E. Griffin, and
H. L. Robinson. Unpublished data.
|
| 48.
|
Vidal, S.,
J. Curran, and D. Kolakofsky.
1990.
Editing of the Sendai virus P/C mRNA by G insertion occurs during mRNA synthesis via a virus-encoded activity.
J. Virol.
64:239-246[Abstract/Free Full Text].
|
| 49.
|
Wardrop, E. A., and D. J. Briedis.
1991.
Characterization of V protein in measles virus-infected cells.
J. Virol.
65:3421-3428[Abstract/Free Full Text].
|
| 50.
|
White, R. G., and J. F. Boyd.
1986.
The effect of measles on the thymus and other lymphoid tissues.
Clin. Exp. Immunol.
30:1067-1073.
|
| 51.
|
Yamada, H.,
T. Omata-Yamada,
J. Taira,
K. Mizumoto, and K. Iwasaki.
1990.
Association of the Sendai virus C protein with nucleocapsids.
Arch. Virol.
113:245-253[Medline].
|
Journal of Virology, October 1998, p. 7754-7761, Vol. 72, No. 10
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Nakatsu, Y., Takeda, M., Iwasaki, M., Yanagi, Y.
(2009). A Highly Attenuated Measles Virus Vaccine Strain Encodes a Fully Functional C Protein. J. Virol.
83: 11996-12001
[Abstract]
[Full Text]
-
Nakatsu, Y., Takeda, M., Ohno, S., Shirogane, Y., Iwasaki, M., Yanagi, Y.
(2008). Measles Virus Circumvents the Host Interferon Response by Different Actions of the C and V Proteins. J. Virol.
82: 8296-8306
[Abstract]
[Full Text]
-
Devaux, P., Hodge, G., McChesney, M. B., Cattaneo, R.
(2008). Attenuation of V- or C-Defective Measles Viruses: Infection Control by the Inflammatory and Interferon Responses of Rhesus Monkeys. J. Virol.
82: 5359-5367
[Abstract]
[Full Text]
-
Rennick, L. J., Duprex, W. P., Rima, B. K.
(2007). Measles virus minigenomes encoding two autofluorescent proteins reveal cell-to-cell variation in reporter expression dependent on viral sequences between the transcription units. J. Gen. Virol.
88: 2710-2718
[Abstract]
[Full Text]
-
Nakatsu, Y., Takeda, M., Ohno, S., Koga, R., Yanagi, Y.
(2006). Translational Inhibition and Increased Interferon Induction in Cells Infected with C Protein-Deficient Measles Virus. J. Virol.
80: 11861-11867
[Abstract]
[Full Text]
-
Yanagi, Y., Takeda, M., Ohno, S.
(2006). Measles virus: cellular receptors, tropism and pathogenesis.. J. Gen. Virol.
87: 2767-2779
[Abstract]
[Full Text]
-
Cruz, C. D., Palosaari, H., Parisien, J.-P., Devaux, P., Cattaneo, R., Ouchi, T., Horvath, C. M.
(2006). Measles Virus V Protein Inhibits p53 Family Member p73.. J. Virol.
80: 5644-5650
[Abstract]
[Full Text]
-
Takeda, M., Ohno, S., Seki, F., Nakatsu, Y., Tahara, M., Yanagi, Y.
(2005). Long Untranslated Regions of the Measles Virus M and F Genes Control Virus Replication and Cytopathogenicity. J. Virol.
79: 14346-14354
[Abstract]
[Full Text]
-
Takeuchi, K., Takeda, M., Miyajima, N., Ami, Y., Nagata, N., Suzaki, Y., Shahnewaz, J., Kadota, S.-i., Nagata, K.
(2005). Stringent Requirement for the C Protein of Wild-Type Measles Virus for Growth both In Vitro and in Macaques. J. Virol.
79: 7838-7844
[Abstract]
[Full Text]
-
Devaux, P., Cattaneo, R.
(2004). Measles Virus Phosphoprotein Gene Products: Conformational Flexibility of the P/V Protein Amino-Terminal Domain and C Protein Infectivity Factor Function. J. Virol.
78: 11632-11640
[Abstract]
[Full Text]
-
Ohno, S., Ono, N., Takeda, M., Takeuchi, K., Yanagi, Y.
(2004). Dissection of measles virus V protein in relation to its ability to block alpha/beta interferon signal transduction. J. Gen. Virol.
85: 2991-2999
[Abstract]
[Full Text]
-
Miyajima, N., Takeda, M., Tashiro, M., Hashimoto, K., Yanagi, Y., Nagata, K., Takeuchi, K.
(2004). Cell tropism of wild-type measles virus is affected by amino acid substitutions in the P, V and M proteins, or by a truncation in the C protein. J. Gen. Virol.
85: 3001-3006
[Abstract]
[Full Text]
-
Yoneda, M., Miura, R., Barrett, T., Tsukiyama-Kohara, K., Kai, C.
(2004). Rinderpest Virus Phosphoprotein Gene Is a Major Determinant of Species-Specific Pathogenicity. J. Virol.
78: 6676-6681
[Abstract]
[Full Text]
-
von Messling, V., Springfeld, C., Devaux, P., Cattaneo, R.
(2003). A Ferret Model of Canine Distemper Virus Virulence and Immunosuppression. J. Virol.
77: 12579-12591
[Abstract]
[Full Text]
-
Mebatsion, T., de Vaan, L. T. C., de Haas, N., Romer-Oberdorfer, A., Braber, M.
(2003). Identification of a Mutation in Editing of Defective Newcastle Disease Virus Recombinants That Modulates P-Gene mRNA Editing and Restores Virus Replication and Pathogenicity in Chicken Embryos. J. Virol.
77: 9259-9265
[Abstract]
[Full Text]
-
Huang, Z., Krishnamurthy, S., Panda, A., Samal, S. K.
(2003). Newcastle Disease Virus V Protein Is Associated with Viral Pathogenesis and Functions as an Alpha Interferon Antagonist. J. Virol.
77: 8676-8685
[Abstract]
[Full Text]
-
Palosaari, H., Parisien, J.-P., Rodriguez, J. J., Ulane, C. M., Horvath, C. M.
(2003). STAT Protein Interference and Suppression of Cytokine Signal Transduction by Measles Virus V Protein. J. Virol.
77: 7635-7644
[Abstract]
[Full Text]
-
Neumann, G., Whitt, M. A., Kawaoka, Y.
(2002). A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned?. J. Gen. Virol.
83: 2635-2662
[Abstract]
[Full Text]
-
Bankamp, B., Kearney, S. P., Liu, X., Bellini, W. J., Rota, P. A.
(2002). Activity of Polymerase Proteins of Vaccine and Wild-Type Measles Virus Strains in a Minigenome Replication Assay. J. Virol.
76: 7073-7081
[Abstract]
[Full Text]
-
Hashimoto, K., Ono, N., Tatsuo, H., Minagawa, H., Takeda, M., Takeuchi, K., Yanagi, Y.
(2002). SLAM (CD150)-Independent Measles Virus Entry as Revealed by Recombinant Virus Expressing Green Fluorescent Protein. J. Virol.
76: 6743-6749
[Abstract]
[Full Text]
-
Vincent, S., Tigaud, I., Schneider, H., Buchholz, C. J., Yanagi, Y., Gerlier, D.
(2002). Restriction of Measles Virus RNA Synthesis by a Mouse Host Cell Line: trans-Complementation by Polymerase Components or a Human Cellular Factor(s). J. Virol.
76: 6121-6130
[Abstract]
[Full Text]
-
Parks, C. L., Lerch, R. A., Walpita, P., Wang, H.-P., Sidhu, M. S., Udem, S. A.
(2001). Comparison of Predicted Amino Acid Sequences of Measles Virus Strains in the Edmonston Vaccine Lineage. J. Virol.
75: 910-920
[Abstract]
[Full Text]
-
Parks, C. L., Lerch, R. A., Walpita, P., Wang, H.-P., Sidhu, M. S., Udem, S. A.
(2001). Analysis of the Noncoding Regions of Measles Virus Strains in the Edmonston Vaccine Lineage. J. Virol.
75: 921-933
[Abstract]
[Full Text]
-
Mebatsion, T., Verstegen, S., De Vaan, L. T. C., Römer-Oberdörfer, A., Schrier, C. C.
(2001). A Recombinant Newcastle Disease Virus with Low-Level V Protein Expression Is Immunogenic and Lacks Pathogenicity for Chicken Embryos. J. Virol.
75: 420-428
[Abstract]
[Full Text]
-
Takeda, M., Takeuchi, K., Miyajima, N., Kobune, F., Ami, Y., Nagata, N., Suzaki, Y., Nagai, Y., Tashiro, M.
(2000). Recovery of Pathogenic Measles Virus from Cloned cDNA. J. Virol.
74: 6643-6647
[Abstract]
[Full Text]
-
Mrkic, B., Odermatt, B., Klein, M. A., Billeter, M. A., Pavlovic, J., Cattaneo, R.
(2000). Lymphatic Dissemination and Comparative Pathology of Recombinant Measles Viruses in Genetically Modified Mice. J. Virol.
74: 1364-1372
[Abstract]
[Full Text]
-
Duprex, W. P., McQuaid, S., Hangartner, L., Billeter, M. A., Rima, B. K.
(1999). Observation of Measles Virus Cell-to-Cell Spread in Astrocytoma Cells by Using a Green Fluorescent Protein-Expressing Recombinant Virus. J. Virol.
73: 9568-9575
[Abstract]
[Full Text]
-
Valsamakis, A., Auwaerter, P. G., Rima, B. K., Kaneshima, H., Griffin, D. E.
(1999). Altered Virulence of Vaccine Strains of Measles Virus after Prolonged Replication in Human Tissue. J. Virol.
73: 8791-8797
[Abstract]
[Full Text]
-
Duprex, W. P., Duffy, I., McQuaid, S., Hamill, L., Cosby, S. L., Billeter, M. A., Schneider-Schaulies, J., ter Meulen, V., Rima, B. K.
(1999). The H Gene of Rodent Brain-Adapted Measles Virus Confers Neurovirulence to the Edmonston Vaccine Strain. J. Virol.
73: 6916-6922
[Abstract]
[Full Text]
-
Valentin, H., Azocar, O., Horvat, B., Williems, R., Garrone, R., Evlashev, A., Toribio, M. L., Rabourdin-Combe, C.
(1999). Measles Virus Infection Induces Terminal Differentiation of Human Thymic Epithelial Cells. J. Virol.
73: 2212-2221
[Abstract]
[Full Text]
-
Escoffier, C., Manié, S., Vincent, S., Muller, C. P., Billeter, M., Gerlier, D.
(1999). Nonstructural C Protein Is Required for Efficient Measles Virus Replication in Human Peripheral Blood Cells. J. Virol.
73: 1695-1698
[Abstract]
[Full Text]